目的 制备和厚朴酚环糊精纳米海绵,考察环糊精纳米海绵对和厚朴酚的增溶作用,并对其理化性质进行初步考察。方法 采用β-环糊精与碳酸二苯酯合成环糊精纳米海绵,并用红外光谱法(FT-IR)和热分析法(DSC)进行验证。结果 和厚朴酚环糊精纳米海绵在DSC中无和厚朴酚的特征吸收峰,FT-IR中1 780 cm-1左右出现新的羰基峰。体外释放实验中和厚朴酚环糊精纳米海绵5 h的累积释放为88.57%,而和厚朴酚混悬液仅为46.55%。纳米海绵使和厚朴酚在水中的溶解度增加了8.87倍。结论 成功制备了和厚朴酚环糊精纳米海绵,显著提高了和厚朴酚的溶解度。
Abstract
OBJECTIVE To prepare the honokiol-loaded β-cyclodextrin-based nanosponges (HK-NSP) and investigate their physicochemical properties. METHODS β-Cyclodextrin-based nanosponges (NSP) was obtained by reacting β-cyclodextrin with diphenyl carbonate and the effect of NSP on honokiol solubilization was investigated. Moreover,NSP and HK-NSP were validated by FT-IR and DSC. RESULTS The FT-IR of HK-NSP showed the presence of the carbonate bond as evidenced by a peak at 1 780 cm-1,and the DSC of HK-NSP did not showed the melting peak corresponding to drug fusion. The percentage of HK released from NSP after 5 h in phosphate buffer solution was 88.57%,and that from HK suspension was only 46.55%. Moreover,NSP showed 8.87 times solubilization efficiency for HK. CONCLUSION HK-NSP are successfully prepared,and the solubility of HK is improved by the NSP obviously.
关键词
和厚朴酚 /
β-环糊精 /
纳米海绵 /
溶解度
{{custom_keyword}} /
Key words
honokiol /
β-cyclodextrin /
nanosponge /
solubility
{{custom_keyword}} /
中图分类号:
R284
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] TROTTA F,CAVALLI R. Characterization and application of new hyper-cross-linked cyclodextrins[J]. Compos Interfaces,2009,16:39-48.
[2] SWAMINATHAN S,PASTERO L,SERPE L,et al. Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization,stability and cytotoxicity[J]. Eur J Pharm Biopharm,2010,74:193-201.
[3] CAVALLI R,TROTTA F,TUMIATTI W. Cyclodextrin-based nanosponges for drug delivery[J]. J Incl Phenom Macro,2006,56:209-213.
[4] SWAMINATHAN S,VAVIA P R,TROTTA F,et al. Formulation of β cyclodextrin based nanosponges of itraconazole[J]. J Incl Phenom Macro,2007,57:89-94.
[5] WANG C L,LAI X P,WU A G. Experimental studies of honokiol in combination with artemisinin on anti-tumor effect of SPC-A-1 cells in vitro[J]. Chin Pharm J(中国药学杂志),2011,46(21):1639-1642.
[6] HU H,ZHANG X X,WANG Y Y,et al. Honokiol inhibits arterial thrombosis through endothelial cell protection and stimulation of prostacyclin[J]. Acta Pharmacol Sin(中国药理学报),2005,26(9):1063-1068.
[7] LIOU K T,LIN S M,HUANG S S,et al. Honikiol ameliorates cerebral infarction from ischemia-reperfusion injury in rats[J]. Planta Med,2003,69(2):130-134.
[8] ZHAO C,LIU Z Q. Comparison of antioxidant abilities of magnoloi and honokiol to scavenge radicals and to protect DNA[J]. Biochimie,2011,93(10):1755-1760.
[9] WANG X,DUAN X,YANG G,et al. Honokiol crosses BBB and BCS-FB,and inhibits brain humor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model[J]. PLoS One,2011,6(4):e18490.
[10] QIN J,LI X T,ZHAO C J,et al. Machnism of anti-nasopharyngeal carcinoma effect of magnolol and honokiol[J]. Chin Tradit Herb Drugs(中草药),2015,46(2):226-230.
[11] Barbara Mognetti,Alessandro Barberis,Silvia Marino,et al. In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation[J]. J Incl Phenom Macrocycl Chem,2012,74:201-210.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
重庆市自然科学基金资助项目(cstc2012jjA10021);高等学校博士学科点专项科研基金(20125503120003);重庆医科大学大学生科学研究与创新实验资助项目(201432,201244,201217);重庆市教育委员会科学技术研究项目(KJ120307)
{{custom_fund}}